Switch theme
Sign up to access all valuation multiples
Medicover AB is an international healthcare and diagnostic services, provider. It offers a broad spectrum of healthcare services via an extensive network of ambulatory clinics, hospitals, specialty-care facilities, and laboratories. The company offers its services through two segments; Diagnostic Services offer a broad range of laboratory testing in all clinical pathology areas in Germany, Romania, Poland, and Ukraine; and Healthcare Services offer high-quality care based on an Integrated Healthcare Model and Fee-For-Service in Poland, India, and Romania. It generates maximum revenue from the Healthcare Services segment. Geographically, it derives a majority of its revenue from Poland and also has a presence in Romania; Germany; Ukraine; India, and Other Countries.
1995
31.6K+
LTM Revenue $27.8B
LTM EBITDA $4.1B
$5.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medicover has a last 12-month revenue (LTM) of $27.8B and a last 12-month EBITDA of $4.1B.
In the most recent fiscal year, Medicover achieved revenue of $216M and an EBITDA of $28.6M.
Medicover expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medicover valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $27.8B | XXX | $216M | XXX | XXX | XXX |
| Gross Profit | $6.3B | XXX | $46.2M | XXX | XXX | XXX |
| Gross Margin | 23% | XXX | 21% | XXX | XXX | XXX |
| EBITDA | $4.1B | XXX | $28.6M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $1.3B | XXX | $8.9M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $453M | XXX | $1.7M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $67.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medicover's stock price is SEK 239 (or $25).
Medicover has current market cap of SEK 35.9B (or $3.7B), and EV of SEK 48.2B (or $5.0B).
See Medicover trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.0B | $3.7B | XXX | XXX | XXX | XXX | $0.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medicover has market cap of $3.7B and EV of $5.0B.
Medicover's trades at 23.0x EV/Revenue multiple, and 173.9x EV/EBITDA.
Equity research analysts estimate Medicover's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medicover has a P/E ratio of 89.0x.
See valuation multiples for Medicover and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV (current) | $5.0B | XXX | $5.0B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 23.0x | XXX | XXX | XXX |
| EV/EBITDA | 13.2x | XXX | 173.9x | XXX | XXX | XXX |
| EV/EBIT | 40.6x | XXX | 555.7x | XXX | XXX | XXX |
| EV/Gross Profit | 8.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 89.0x | XXX | 2148.7x | XXX | XXX | XXX |
| EV/FCF | 128.3x | XXX | 345.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedicover's last 12 month revenue growth is 12%
Medicover's revenue per employee in the last FY averaged $7K, while opex per employee averaged $1K for the same period.
Medicover's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medicover's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medicover and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 278% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 296% | XXX | XXX | XXX |
| Rule of 40 | 27% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $7K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medicover acquired XXX companies to date.
Last acquisition by Medicover was XXXXXXXX, XXXXX XXXXX XXXXXX . Medicover acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medicover founded? | Medicover was founded in 1995. |
| Where is Medicover headquartered? | Medicover is headquartered in Sweden. |
| How many employees does Medicover have? | As of today, Medicover has 31.6K+ employees. |
| Who is the CEO of Medicover? | Medicover's CEO is Mr. Fredrik Ragmark. |
| Is Medicover publicy listed? | Yes, Medicover is a public company listed on STO. |
| What is the stock symbol of Medicover? | Medicover trades under MCOV B ticker. |
| When did Medicover go public? | Medicover went public in 2017. |
| Who are competitors of Medicover? | Similar companies to Medicover include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Medicover? | Medicover's current market cap is $3.7B |
| What is the current revenue of Medicover? | Medicover's last 12 months revenue is $27.8B. |
| What is the current revenue growth of Medicover? | Medicover revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Medicover? | Current revenue multiple of Medicover is 1.9x. |
| Is Medicover profitable? | Yes, Medicover is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medicover? | Medicover's last 12 months EBITDA is $4.1B. |
| What is Medicover's EBITDA margin? | Medicover's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Medicover? | Current EBITDA multiple of Medicover is 13.2x. |
| What is the current FCF of Medicover? | Medicover's last 12 months FCF is $422M. |
| What is Medicover's FCF margin? | Medicover's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Medicover? | Current FCF multiple of Medicover is 128.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
